MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025)
MapLight Therapeutics (MPLT) posted Free Cash Flow of -$47.2 million for Q4 2025, down 118.6% sequentially from -$21.6 million in Q4 2024, and down 118.6% YoY from $253.8 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Free Cash Flow (2024 - 2025) Analysis & Trends
MapLight Therapeutics has reported Free Cash Flow for 2 years, with the latest figure at -$47.2 million in Q4 2025.
- Quarterly Free Cash Flow fell 118.6% year-over-year to -$47.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$68.8 million (changed N/A YoY) and the FY2025 annual result came in at -$138.6 million, down 74.17% from the prior year.
- Free Cash Flow retreated to -$47.2 million in Q4 2025 per MPLT's latest filing, from -$21.6 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$21.6 million in Q4 2024 and troughed at -$47.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | MapLight Therapeutics | 642.40 Mn | 642.40 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -47.21 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Dec 31, 2024 | -21.59 Mn |